Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Wei, Andrew H.
~ 39000  Ergebnisse:
Personensuche X
?
1

Putting the STING back into BH3-mimetic drugs for TP53-muta..:

Diepstraten, Sarah T. ; Yuan, Yin ; La Marca, John E....
Cancer Cell.  42 (2024)  5 - p. 850-868.e9 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Real-world Effectiveness of Azacitidine in Treatment-Naive ..:

Rajakumaraswamy, Nishanthan ; Gandhi, Mitul ; Wei, Andrew H....
Clinical Lymphoma Myeloma and Leukemia.  24 (2024)  4 - p. 260-268.e2 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Olutasidenib in post-venetoclax patients with mutant isocit..:

Cortes, Jorge ; Jonas, Brian A. ; Schiller, Gary...
Leukemia & Lymphoma.  , 2024
Link: https://doi.org/10.1080/..
 
?
4

Clinical evaluation of complete remission (CR) with partial..:

Appelbaum, Jacob S. ; Wei, Andrew H. ; Mandrekar, Sumithra J....
Leukemia.  38 (2024)  2 - p. 389-392 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Venetoclax–based low intensity therapy in molecular failure..:

Jimenez-Chillon, Carlos ; Othman, Jad ; Taussig, David...
Blood Advances.  8 (2024)  2 - p. 343-352 , 2024
Link: https://doi.org/10.1182/..
 
?
6

Azacitidine Monotherapy in Patients With Treatment-Naïve Hi..:

Hasegawa, Ken ; Wei, Andrew H ; Garcia-Manero, Guillermo...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  2 - p. 127-137 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Acquired mutations in BAX confer resistance to BH3-mimetic ..:

Moujalled, Donia M. ; Brown, Fiona C. ; Chua, Chong Chyn...
Blood.  141 (2023)  6 - p. 634-644 , 2023
Link: https://doi.org/10.1182/..
 
?
8

Venetoclax treatment in patients with cancer has limited im..:

Teh, Charis E. ; Peng, Hongke ; Luo, Meng-Xiao...
Blood Advances.  7 (2023)  12 - p. 2733-2745 , 2023
Link: https://doi.org/10.1182/..
 
?
9

Cusatuzumab plus azacitidine in newly diagnosed acute myelo..:

Pabst, Thomas ; Papayannidis, Cristina ; Demirkan, Fatih...
The Lancet Haematology.  10 (2023)  11 - p. e902-e912 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Olutasidenib (FT-2102) induces durable complete remissions ..:

de Botton, Stéphane ; Fenaux, Pierre ; Yee, Karen...
Blood Advances.  7 (2023)  13 - p. 3117-3127 , 2023
Link: https://doi.org/10.1182/..
 
?
11

TP53 status and impact on AML prognosis within the ELN 2022..:

Fleming, Shaun ; Tsai, Xavier Cheng-Hong ; Morris, Rhiannon..
Blood.  142 (2023)  23 - p. 2029-2033 , 2023
Link: https://doi.org/10.1182/..
 
?
12

BCL2 Inhibition: A New Paradigm for the Treatment of AML an..:

Wei, Andrew H. ; Roberts, Andrew W.
HemaSphere.  7 (2023)  6 - p. e912 , 2023
Link: https://doi.org/10.1097/..
 
?
13

Survival outcomes with oral azacitidine maintenance in pati..:

Wei, Andrew H. ; Roboz, Gail J. ; Dombret, Herve...
Haematologica.  , 2023
Link: https://doi.org/10.3324/..
 
?
14

An agenda to advance research in myelodysplastic syndromes:..:

Stahl, Maximilian ; Abdel-Wahab, Omar ; Wei, Andrew H....
Blood Advances.  7 (2023)  12 - p. 2709-2714 , 2023
Link: https://doi.org/10.1182/..
 
?
15

Measurable residual disease monitoring in patients with acu..:

Ravandi, Farhad ; Cloos, Jacqueline ; Buccisano, Francesco...
American Journal of Hematology.  98 (2023)  12 - p. 1847-1855 , 2023
Link: https://doi.org/10.1002/..
 
1-15